Smoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report

The use of mogamulizumab needs careful consideration because of severe adverse reactions such as graft‐vs‐host disease. However, refractory specific skin lesions of smoldering type adult T‐cell leukemia/lymphoma can be effectively treated with mogamulizumab when patients have no opportunity to recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishikawa, Yotaro, Mochida, Kosuke, Kubo, Tamaki, Horikawa, Nagako, Nemoto, Rieko, Amano, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509667/
https://www.ncbi.nlm.nih.gov/pubmed/31110745
http://dx.doi.org/10.1002/ccr3.2155
_version_ 1783417287847444480
author Nishikawa, Yotaro
Mochida, Kosuke
Kubo, Tamaki
Horikawa, Nagako
Nemoto, Rieko
Amano, Masahiro
author_facet Nishikawa, Yotaro
Mochida, Kosuke
Kubo, Tamaki
Horikawa, Nagako
Nemoto, Rieko
Amano, Masahiro
author_sort Nishikawa, Yotaro
collection PubMed
description The use of mogamulizumab needs careful consideration because of severe adverse reactions such as graft‐vs‐host disease. However, refractory specific skin lesions of smoldering type adult T‐cell leukemia/lymphoma can be effectively treated with mogamulizumab when patients have no opportunity to receive hematopoietic stem cell transplantation like our case.
format Online
Article
Text
id pubmed-6509667
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65096672019-05-20 Smoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report Nishikawa, Yotaro Mochida, Kosuke Kubo, Tamaki Horikawa, Nagako Nemoto, Rieko Amano, Masahiro Clin Case Rep Case Reports The use of mogamulizumab needs careful consideration because of severe adverse reactions such as graft‐vs‐host disease. However, refractory specific skin lesions of smoldering type adult T‐cell leukemia/lymphoma can be effectively treated with mogamulizumab when patients have no opportunity to receive hematopoietic stem cell transplantation like our case. John Wiley and Sons Inc. 2019-04-16 /pmc/articles/PMC6509667/ /pubmed/31110745 http://dx.doi.org/10.1002/ccr3.2155 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Nishikawa, Yotaro
Mochida, Kosuke
Kubo, Tamaki
Horikawa, Nagako
Nemoto, Rieko
Amano, Masahiro
Smoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report
title Smoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report
title_full Smoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report
title_fullStr Smoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report
title_full_unstemmed Smoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report
title_short Smoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report
title_sort smoldering type adult t‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐cc chemokine receptor 4 monoclonal antibody)—a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509667/
https://www.ncbi.nlm.nih.gov/pubmed/31110745
http://dx.doi.org/10.1002/ccr3.2155
work_keys_str_mv AT nishikawayotaro smolderingtypeadulttcellleukemialymphomaeffectivelytreatedwithmogamulizumabanticcchemokinereceptor4monoclonalantibodyacasereport
AT mochidakosuke smolderingtypeadulttcellleukemialymphomaeffectivelytreatedwithmogamulizumabanticcchemokinereceptor4monoclonalantibodyacasereport
AT kubotamaki smolderingtypeadulttcellleukemialymphomaeffectivelytreatedwithmogamulizumabanticcchemokinereceptor4monoclonalantibodyacasereport
AT horikawanagako smolderingtypeadulttcellleukemialymphomaeffectivelytreatedwithmogamulizumabanticcchemokinereceptor4monoclonalantibodyacasereport
AT nemotorieko smolderingtypeadulttcellleukemialymphomaeffectivelytreatedwithmogamulizumabanticcchemokinereceptor4monoclonalantibodyacasereport
AT amanomasahiro smolderingtypeadulttcellleukemialymphomaeffectivelytreatedwithmogamulizumabanticcchemokinereceptor4monoclonalantibodyacasereport

Ejemplares similares